Instruments for holistic assessment of Parkinson's disease

Holistic Physical Assessment: A New Framework for Nursing Practice Honoring the Whole Person

Scholars have argued that standard physical assessment is based on a medical framework instead of nursing theories and philosophy. We argue that standard physical assessment is task-oriented, lacking emphasis on the whole-person and neglecting a least-to-most invasive assessment process. While holistic health assessment is person-centered and multidimensional; addressing aspects such as physical, emotional, and spiritual well-being, there is not a comprehensive explanation on how to holistically perform the physical examination portion of a holistic health assessment. Proposed is a new framework for holistic physical assessment in the hospital environment, honoring the whole-person, their background, and lived experiences. The framework builds on the holistic nursing philosophy, integrative nursing principles, and trauma-informed approach, and systematically arranges physical assessment from least invasive to most. The seven sequential assessment steps incorporate self-care and awareness into the preparation and closure of the assessment-(1) the self, (2) the space, (3) least invasive, (4) moderate invasive, (5) most invasive, (6) the space, and (7) the self. This framework can have significant implications for nursing practice and education settings, providing valuable guidance for a holistic physical assessment that emphasizes whole-person care.

Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease

BACKGROUND

Identifying predictors of incident cognitive impairment (CI), one of the most problematic long-term outcomes, in Parkinson's disease (PD) is highly relevant for personalized medicine and prognostic counseling. The Nonmotor Symptoms Scale (NMSS) provides a global clinical assessment of a range of NMS, reflecting NMS burden (NMSB), and thus may assist in the identification of an "at-risk" CI group based on overall NMSB cutoff scores.

METHODS

To investigate whether specific patterns of PD NMS profiles predict incident CI, we performed a retrospective longitudinal study on a convenience sample of 541 nondemented PD patients taking part in the Nonmotor Longitudinal International Study (NILS) cohort, with Mini-Mental State Examination (MMSE), NMSS, and Scales for Outcomes in PD Motor Scale (SCOPA Motor) scores at baseline and last follow-up (mean 3.2 years) being available.

RESULTS

PD patients with incident CI (i.e., MMSE score ≤ 25) at last follow-up (n = 107) had severe overall NMSB level, significantly worse NMSS hallucinations/perceptual problems and higher NMSS attention/memory scores at baseline. Patients with CI also were older and with more advanced disease, but with no differences in disease duration, dopamine replacement therapy, sex, and comorbid depression, anxiety, and sleep disorders.

CONCLUSIONS

Our findings suggest that a comprehensive baseline measure of NMS and in particular hallucinations and perceptual problems assessed with a validated single instrument can be used to predict incident CI in PD. This approach provides a simple, holistic strategy to predict future CI in this population.

Turkish version of Parkinson Fatigue Scale: Validity and reliability study of binary scoring method

OBJECTIVES

The aim of the present study was to translate and cross-culturally adapt the Parkinson Fatigue Scale (PFS) into Turkish and to evaluate its reliability and validity.

PATIENTS AND METHODS

Between September 2015 and May 2016, a total of 138 patients (84 males, 54 females; mean age 62.8±9.3 years; range, 42 to 83 years) with Parkinson's disease (PD) were included in this study. The Turkish version of the PFS was analyzed for data quality, scaling assumptions, acceptability, reliability, and validity. We used the binary scoring method of the Parkinson Fatigue Scale.

RESULTS

The data quality for the Turkish version of the PFS was excellent. The scaling assumption was acceptable. The scale provided an acceptable internal consistency (Cronbach's alpha was 0.955 for a test and 0.941 for a retest, and corrected item-to-total correlations were ranged from 0.478 to 0.849. The test-retest reliability (correlation coefficients were ranged from 0.650 to 0.875) was adequate. Although the total binary score of the PFS was not associated with demographic and clinical data, it was significantly correlated with some of the clinical rating scale scores, including the Unified Parkinson's Disease Rating Scale, Schwab & England Activities of Daily Living Scale, Hospital Anxiety and Depression Scale, Epworth Sleepiness Scale, Pittsburg Sleep Quality Index, 36-item Short Form Health Survey, 39-item Parkinson's Disease Questionnaire, and Fatigue Severity Scale.

CONCLUSION

The Turkish version of the PFS is an acceptable, valid, and reliable tool for the assessment of fatigue in PD patients.

Eryptosis as a marker of Parkinson's disease

A major trend in recent Parkinson's disease (PD) research is the investigation of biological markers that could help in identifying at-risk individuals or to track disease progression and response to therapies. Central to this is the knowledge that inflammation is a known hallmark of PD and of many other degenerative diseases. In the current work, we focus on inflammatory signalling in PD, using a systems approach that allows us to look at the disease in a more holistic way. We discuss cyclooxygenases, prostaglandins, thromboxanes and also iron in PD. These particular signalling molecules are involved in PD pathophysiology, but are also very important in an aberrant coagulation/hematology system. We present and discuss a hypothesis regarding the possible interaction of these aberrant signalling molecules implicated in PD, and suggest that these molecules may affect the erythrocytes of PD patients. This would be observable as changes in the morphology of the RBCs and of PD patients relative to healthy controls. We then show that the RBCs of PD patients are indeed rather dramatically deranged in their morphology, exhibiting eryptosis (a kind of programmed cell death). This morphological indicator may have useful diagnostic and prognostic significance.

Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits

Electrical stimulation of the subthalamic nucleus is an established treatment for patients with advanced Parkinson's disease with pharmacologically unresponsive fluctuations. Compared with pharmacological treatment, subthalamic neurostimulation significantly improves motor symptoms, particularly during the phases of poor response to drug treatment, and reduces the severity of dyskinesias. Importantly, it also significantly improves quality of life and other integral measures of disease severity. The treatment response can last for more than 10 years, although there is no evidence that levodopa-resistant symptoms are delayed by subthalamic neurostimulation. At present, the mean disease duration for patients at the time of implantation is 12 years. In a recent study (EARLYSTIM) in patients with a disease duration of 7·5 years and fluctuations for 1·5 years, similar improvements in clinical outcomes were reported. These findings suggest that neurostimulation of the subthalamic nucleus could be used earlier in the disease course for carefully selected patients if the benefits of the treatment are weighed against the surgical risks and the lifelong need for specialised care by an experienced team. As mobility is consistently improved during the times with poor mobility by reducing fluctuations and delaying levodopa-sensitive complications, we propose that this treatment changes the disease course.

Three-dimensional rodent motion analysis and neurodegenerative disorders

BACKGROUND

Three-dimensional (3D) motion analysis is established in investigating, human pathological motion. In the field of gait, its use results in the objective identification of primary, and secondary causes of deviations, many current interventions are the result of pre- and post-testing, and it was shown recently that it can result in decreased number of surgeries and overall cost of care. Consequently, recent attempts have implemented 3D motion analysis using rat models to study, parkinsonism. However, to-date, a 3D user friendly analytical approach using rodent models to, identify etiologies of age-related motor impairment and accompanying pathologies has not been, implemented.

NEW METHOD

We have developed and presented all aspects of a 3D, three body-segment rodent model, to analyze motions of the lower, upper and head segments between rodents of parkinsonism-type and, normal aging during free walking. Our model does not require transformation matrices to describe the, position of each body-segment. Because body-segment positions are not considered to consist of three, rotations about the laboratory axes, the rotations are not sequence dependent.

RESULTS

Each body-segment demonstrated distinct 3D movement patterns. The parkinsonism-type, genotype walked slower with less range of motion, similarly to patients with parkinsonism.

COMPARISON WITH EXISTING METHODS

This is the first model considering the rodent's body as three, distinct segments. To the best of our knowledge, it is the first model to ever consider and report the 3D, head motion patterns.

CONCLUSIONS

This novel approach will allow unbiased analysis of spontaneous locomotion in mouse, models of parkinsonism or normal aging.